Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
Showing 3,321 - 3,340 results of 21,342 for search '(( significantly ((lower decrease) OR (greatest decrease)) ) OR ( significant decrease decrease ))', query time: 0.54s Refine Results
  1. 3321
    Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant.

    Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 3322
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3323
    Flowchart of the exclusive breastfeeding mothers (EBF) and the exclusive breastfeeding mother-donors (EBF+) who participated in the study.

    Flowchart of the exclusive breastfeeding mothers (EBF) and the exclusive breastfeeding mother-donors (EBF+) who participated in the study. by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 3324
    Timeline of monitoring of exclusive breastfeeding mothers (EBF) and exclusive breastfeeding – donors (EBF+).

    Timeline of monitoring of exclusive breastfeeding mothers (EBF) and exclusive breastfeeding – donors (EBF+). by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 3325
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 3326
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 3327
    <i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces.

    <i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 3328
    Data supporting the findings of this study.

    Data supporting the findings of this study. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 3329
    Comparison of densitometric, biochemical, and hormonal variables, and bone turnover markers of EBF + 6 months versus EBF + one year postpartum.

    Comparison of densitometric, biochemical, and hormonal variables, and bone turnover markers of EBF + 6 months versus EBF + one year postpartum. by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 3330
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 3331
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 3332
    I Optimal design for optimization of Axitinib loaded Spanlastics.

    I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 3333
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 3334
    ANOVA for I optimal design of Axitinib loaded Spanlastics.

    ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 3335
    The kinetic release data of the optimized formula compared to drug suspension.

    The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 3336
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 3337
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 3338
    Oligonucleotides used in this study.

    Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 3339
    Open data.

    Open data. by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 3340
    Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions.

    Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: